Fig. 2

Auxillin-1 and 2 correlate with clinical outcome of ALL patients. In an analysis, ALL patients (ECOG E2993 [15, 16], n = 36, logrank test P = 0.02) were segregated into two groups based on high or low mRNA levels in respect to the median mRNA value of the Auxilin-1 and -2 probeset and the overall survival (OS) was assessed (a, b). Similarly, in a multivariate analysis; the ALL patients were segregated in two groups, according on high or low mRNA levels of Auxilin-1 and -2 (c), XBP1 and Auxilin-1 (d) or XBP1 and Auxilin-2 and overall survival was assessed (e). The patient subcohorts are mentioned in the according headlines (a–d). Auxilin-2 mRNA levels were measured by qRT-PCR in Ph⁺ ALL and CML cell lines (SUP-B15, TOM-1 and KCL-22) treated with or without the TKI Nilotinib for 16 h (5 µM) (n = 3) (f) and with or without the IRE1 RNase inhibitor MKC-8866 for 16 h (30 µM MKC-8866) (n = 3) (g)